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ABSTRACT
Finding the best technique to identify BRAF mutations with a high sensitivity 
and specificity is mandatory for accurate patient selection for target therapy. 
BRAF mutation frequency ranges from 40 to 60% depending on melanoma clinical 
characteristics and detection technique used.
Intertumoral heterogeneity could lead to misinterpretation of BRAF mutational 
status; this is especially important if testing is performed on primary specimens, when 
metastatic lesions are unavailable.
Aim of this study was to identify the best combination of methods for detecting 
BRAF mutations (among peptide nucleic acid – PNA- clamping real-time PCR, 
immunohistochemistry and capillary sequencing) and investigate BRAF mutation 
heterogeneity in a series of 100 primary melanomas and a subset of 25 matched 
metastatic samples.
Overall, we obtained a BRAF mutation frequency of 62%, based on the 
combination of at least two techniques. Concordance between mutation status in 
primary and metastatic tumor was good but not complete (67%), when agreement 
of at least two techniques were considered. Next generation sequencing was used to 
quantify the threshold of detected mutant alleles in discordant samples. Combining 
different methods excludes that the observed heterogeneity is technique-based. 
We propose an algorithm for BRAF mutation testing based on agreement between 
immunohistochemistry and PNA; a third molecular method could be added in case of 
discordance of the results. Testing the primary tumor when the metastatic sample is 
unavailable is a good option if at least two methods of detection are used, however 
the presence of intertumoral heterogeneity or the occurrence of additional primaries 
should be carefully considered.
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INTRODUCTION
The discovery of BRAF mutations in melanoma 
and the development of specific BRAF inhibitors has 
led to significant advances in treatment of metastatic 
melanoma, which has now been further improved by the 
use of new immunologic therapy [1]. Melanoma patients 
with metastatic or unresectable disease, according to 
recent NCCN guidelines [2], should be tested for BRAF 
V600 mutations to evaluate therapy options. However, 
there is no consensus on the best BRAF testing method, 
except for the need for a certified laboratory. In Italy, 
national guidelines from the Italian association of medical 
oncology and Pathology (AIOM-SIAPEC) point to 
standardization of different testing methods with internal 
controls, fast turnaround time of results, and the additional 
value of CE-IVD techniques [3].
BRAF mutation rate in melanoma ranges from 40 
to 60% of cases [4–7]. This difference, besides reflecting 
clinical characteristics of the cohort studied, could also 
be due to the different methods used: a wide range of 
detection techniques is available, including classical 
capillary sequencing, pyrosequencing, next generation 
sequencing techniques (NGS), several real-time PCR (RT-
PCR) based methods and immunohistochemistry (IHC) 
antibodies [8–14]; some of these methods have obtained 
CE-IVD certification.
Since the approval of BRAF inhibitors for the 
treatment of metastatic melanoma, the importance of 
BRAF heterogeneity in melanoma samples has gained 
much attention [15]. Tumour heterogeneity and the 
evolution of branching tumour subclones are a challenge 
even for multi-targeted therapies and intermittent regimens 
[16]. Currently, general advice is to test metastatic 
melanoma for the presence of BRAF mutation in the most 
recent metastatic sample. In some instances, biopsy from 
metastasis is unavailable, so checking mutational status 
in the primary tumor has been proposed as an alternative 
[17]. The consistency in BRAF mutation detection among 
primary and metastatic tumors is however still debated 
[18–20].
In addition, the clinical significance of finding 
BRAF mutation using a high sensitivity technique 
in a low number of cells in the primary tumor is still 
unclear, especially when not confirmed in the metastatic 
sample. Indeed, a different cell clone, driven by other 
mutations, could be positively selected and responsible for 
progression and the development of the metastasis [21].
Currently, data on primary melanoma are scarce, 
as well as data on matched primary and metastatic 
melanomas tested with several high sensitivity techniques 
[21–24]. Generally, IHC staining shows good consistency 
between primary and metastatic samples, although limited 
by a lower sensitivity compared to recent molecular 
techniques, which have, conversely, the disadvantage of 
relying on DNA quantity and quality [25].
Overall, while recent data applying IHC point to 
intra and inter tumor homogeneity of BRAF-mutated 
expression, the issue of genetic heterogeneity is still 
debated [23].
Aim of this study was to identify the best 
combination of methods for detecting BRAF mutations 
and investigate BRAF mutation heterogeneity within 100 
primary melanomas and between primary melanoma and 
a subset of 25 matched metastatic samples. Furthermore, 




Our cohort included 94 primary cutaneous 
melanomas, 4 mucosal melanomas and 2 uveal 
melanomas. Median follow-up for survivors was 74 
months. During this period, 22 patients relapsed and 
19 patients died, of which 13 deaths were melanoma-
related. Twelve patients developed multiple melanomas. 
A summary of patients characteristics is shown in Table 1. 
In addition 25 metastatic samples, from 15 out of the 22 
patients who relapsed during follow-up, were analyzed. 
Of these, 19 samples were metastatic lymph nodes, and 6 
were distant metastases. In 5 patients, lymph nodes were 
excised at the same time as the primary.
BRAF mutation analysis, using three different 
techniques, reveals a high percentage of V600 
mutations in primary melanomas
We analyzed 100 FFPE samples from primary 
melanoma with three different techniques to determine 
the mutational status of BRAF and test which could be the 
most sensitive method to identify mutations in the BRAF 
V600 codon (Table S1 and Figure 1). We chose PNA 
clamping real-time PCR (here named PNA) and capillary 
sequencing, to compare the sensitivity of the IHC antibody 
specific for the BRAF V600E mutated protein to molecular 
techniques.
PNA identified 66 BRAF V600 mutated samples out 
of 98 (67,3%) and 32 wild type (33%); two samples gave 
invalid results (Figure 1A).
IHC was available for every primary melanoma 
sample, identifying 59 mutated samples with positive 
staining (59%) and 41 with negative staining. Among the 
positive samples, 52 showed an homogeneous staining 
pattern, while 7 showed an heterogeneous pattern (% of 
stained cells <95%), in a percentage variable between 10 
and 80% (Figure 1A-1E).
Classical capillary sequencing was successful 
in 86 samples out 100, identifying 53 mutated samples 
(61,6%); 51 (96%) presented the canonical BRAF V600E 
mutation (c.1799 T>A), one (2%) presented the same 
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Table 1: Clinical and pathological features of the 100 primary melanomas in the study cohort
 Number of Patients
(n=100)
Gender and age  
 Male 45
 Female 55
 Median Age 52 years
Primary tumor site  
 Trunk 50
 Upper limb 16
 Lower limb 24
 Head and Neck 4
 Uveal 2
 Mucosal 4















Tumor stage  
 I-II 86
 III-IV 14
Prognostic features  
 Median follow-up 74 months (range 47 Q1 -158 Q3)
 Alive 81
 Dead 19
 Melanoma-related deaths 13
 Multiple primary melanomas 12
 Relapse 22
*The unclassified cases correspond to 2 uveal and 4 mucosal melanomas, not classified using Breslow. (SSM: superficial 
spreading melanoma)
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amino acidic change V600E due to the less frequent 
substitution c.1799_1800delTGinsAA, (also called 
V600E2) and one (2%) the BRAF V600K mutation 
(c.1798_1799delGTinsAA).
Overall, BRAF mutation rate in 100 primary 
melanoma samples was 67,3% when analyzed by PNA, 
and 59% when the V600E mutation was assessed using 
the VE1 specific antibody for IHC staining. The classical 
capillary sequencing technique is sensitive (61,6%) but 
shows poor performance as 14 cases were not amplified. 
(Figure 1A). At least one of these highly sensitive methods 
identified a positive result in 71% of cases.
Sanger sequencing, PNA analysis and IHC provided 
the same results in 63 cases (46 positive and 21 negative 
for BRAF mutation). BRAF mutation rate was 62% if we 
consider the results obtained with at least two methods. 
Overall, agreement among the 3 methods was substantial 
(Light’s k= 0.701, z=3.95, p=7.77e-05).
Interestingly, two samples invalid at PNA analysis 
were found to be positive by IHC (and one of them also at 
capillary sequencing) (Figure 1F and Table S1).
Characterization of BRAF mutational status in 
matched primary and metastatic melanomas 
reveals a good consistency
We analyzed 25 samples of metastatic melanomas, 
coupled with their primary tumors, deriving from 15 of the 
22 patients who relapsed, using the same three methods 
mentioned above for the primary samples: PNA, IHC and 
capillary sequencing (Table 2 and Table 3)
First, we considered the concordance of the 
results obtained with the three techniques, as we 
did for the primary samples: only 5/15 (33%) cases 
showed concordant results with all the three techniques; 
considering the results obtained combining the two 
Figure 1: A combination of IHC and molecular techniques reveals a high percentage of V600 mutations. A. BRAF V600 
different mutation rate and yield in 100 primary melanomas tested by PNA, IHC and capillary sequencing. B-E. representative IHC analysis 
of BRAF positive cases [Magnification 20x (B,D); 40x (C,E)]. F. Comparison among 100 primary melanomas, which gave a positive 
successful result with at least one method. Black Numbers indicate BRAF V600 positive cases obtained with each single technique; red 
numbers show those additional BRAF V600 positive cases obtained with one or two techniques only.
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Table 2: BRAF mutational status in matched primary and metastatic melanomas reveals a good consistency






 4  
PNA V600 wt   +/-  
IHC weak weak   +/+ +/-
Capillary seq V600E wt   +/-  
Cell %/Localization 20/Upper limb 70/LN     
 13 
PNA V600 wt wt  +/-  
IHC weak negative negative  +/- +/-
Capillary seq V600E wt wt  +/-  
Cell %/Localization 50/Lower limb 50/LN 50/LN    
 18 
PNA V600 V600 V600 n.a. +/+  
IHC weak moderate strong moderate +/+ +/+
Capillary seq WT V600E V600E- n.a. -/+  
Cell %/Localization 80/Lower limb 80/Skin 70/Skin 70/LN   
 25 
PNA V600 n.a. wt n.a. +/-  
IHC moderate moderate moderate moderate +/+ +/-
Capillary seq V600E- wt wt n.a. +/-  
Cell %/Localization 80/Lower limb 70/Skin 40/LN 30/LN   
 39 
PNA V600 V600 V600  +/+  
IHC weak moderate strong  +/+ +/+
Capillary seq WT V600E V600E  -/+  
Cell %/Localization 50/Trunk 80/LN 80/Skin    
46 
PNA wt wt   -/-  
IHC negative negative   -/- -/-
Capillary seq n.a. wt   n.a.  
Cell %/Localization 80/Trunk 80/LN     
 55  
PNA V600 wt   +/-  
IHC negative negative   -/- +/-
Capillary seq V600E wt   +/-  
Cell %/Localization 10/Upper limb 80/LN     
 67 
PNA V600 V600   +/+  
IHC weak weak   +/+ +/+
Capillary seq n.a. V600K   n.a.  





PNA V600 V600   +/+  
IHC weak strong   +/+ +/+
Capillary seq V600E V600E   +/+  
Cell %/Localization 70/Trunk 40/LN     
(Continued )
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most sensitive techniques, (IHC and PNA), we observed 
concordance in 67% of cases (10/15); if we considered at 
least two techniques we had concordant results in 100% 
(Table 2). Due to the small sample size (N < 30), inter-
rater agreement for metastatic samples was not calculated 
in order to avoid false results.
Overall there was a high consistency between the 
data relative to BRAF mutation observed in primary 
and matched metastatic melanoma. Ten cases showed 
the same results between the primary and the metastatic 
sample, with the combination of the three methods (67% 
of concordance, considering a result obtained with at least 
two methods). The five discordant cases showed a BRAF 
mutation in the primary, which was not confirmed in the 
metastatic sample. The contrary was never observed (i.e. 
negative primary tumor showing BRAF mutation in the 







PNA V600 V600 V600  +/+  
IHC moderate strong strong  +/+ +/+
Capillary seq V600E2 V600E2 V600E2  +/+  
Cell %/Localization 80/Trunk 60/LN 60/LN    
 75 
PNA V600 wt wt  +/-  
IHC negative negative negative  -/- +/-
Capillary seq V600E wt wt  +/-  
Cell %/Localization 40/Head-Neck 90/LN 80/LN    
 76 
PNA V600 V600   +/+  
IHC moderate strong   +/+ +/+
Capillary seq V600E n.a.   n.a.  
Cell %/Localization 70/Upper limb 90/LN     
 77  
PNA WT wt wt wt -/-  
IHC negative weak weak weak -/+ -/-
Capillary seq WT wt wt wt -/-  
Cell %/Localization 80/Upper limb 70/LN 60/LN 80/Mucosal   
 98  
PNA wt wt   -/-  
IHC negative negative   -/- -/-
Capillary seq wt wt (k601k)   -/-  
Cell %/Localization 80/Mucosal 90/Mucosal     
 100  
PNA wt wt   -/-  
IHC negative negative   -/- -/-
Capillary seq wt wt   -/-  
Cell %/Localization n.a,/Trunk n.a./LN     
Intrapatient overall concordance means that at least two techniques gave the same results in matched samples (M1, M2, 
M3: progressive matched metastatic samples; LN: lymph-node).
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matched metastasis). Interestingly, 4 of the 5 discordant 
cases displayed metastatic lymph nodes which were not 
excised synchronously with the primary tumor.
When analyzing concordance per single method, 
we were able to verify that IHC showed results with the 
highest concordance (in 13/15 cases, 87%), followed by 
PNA (10/15 cases) with a concordance rate of 67% (the 
same observed with the combination of two methods). 
Instead, the concordance with capillary sequencing was 
very low (5/12, 42% of cases) (Table 3).
NGS excludes that inconsistency between 
primary and metastatic sample is due to a low 
threshold of mutated alleles as detected in the 
primary tumor
NGS with a custom designed hot spot panel 
including BRAF gene was used to analyze 3 of the 5 
primary/metastases discordant cases (n. 4, 13 and 25) 
in order to confirm our observations and to quantify 
the threshold of mutated alleles that could be identified 
through the other methods.
We confirmed the positive BRAF mutational status 
obtained with our previous results (Table S1, Table 
2), in primary melanoma at high rates (30, 47 and 41 
% of mutated alleles, respectively) and lack of BRAF 
mutation in the metastatic samples (Figure 2A, 2C, 2D). 
Interestingly, in case 4 we observed a BRAF V600E 
mutation in the primary melanoma, undetectable in the 
paired metastasis, which instead revealed a NRAS Q61R 
mutation (Figure 2A, 2B). A possible explanation was that 
when we checked the history of this patient we found out 
that he was one of the 12 patients who developed multiple 
primary melanomas, before the development of metastatic 
disease (including the analyzed metastasis). Therefore, 
this non-consistency may be explained if the metastasis 
that we found did not originate from the same primary 
melanoma that we analyzed, but from the second primary 
melanoma (never tested because not available in our 
archives, but with a higher metastatic potential because 
of its Breslow level) that could have been NRAS-positive 
and BRAF-negative. For the other non-consistent pairs, no 
other primary melanomas were reported.
DISCUSSION
Mutations in the BRAF oncogene are of increasing 
relevance in clinical oncology, especially after the 
approval of the anti-BRAF molecules in the therapy of 
BRAF positive metastatic melanomas. Therefore, finding 
the best technique to identify BRAF mutations with a high 
sensitivity and specificity is mandatory of accurate patient 
selection.
Here we tested BRAF mutations in a series of 100 
primary melanomas with different techniques. Aim of our 
study was also to investigate intertumoral heterogeneity on 
the basis of the combination of different techniques used 
to detect BRAF mutations. Therefore, we analyzed 100 
samples of primary melanomas using a combination of 
immunohistochemical analyses and real-time polymerase 
chain reaction (PNA in our cohort), in addition to classical 
capillary sequencing. IHC was more effective than 
capillary sequencing for detecting the V600E mutation. 
In a diagnostic setting it is the cheapest and the least time 
consuming technique (as it does not depend on DNA 
extraction) and can work on small melanoma samples.
CE-IVD PNA proved to be the most sensitive 
method in our cohort, as well as highly specific: it 
was also able to detect all mutations at codon 600, 
including the V600K mutation (as confirmed by capillary 
sequencing), while IHC antibody is marketed only for 
V600E identification. Due to its high sensitivity, PNA 
identified 67.3% of BRAF mutated samples, which is, to 
our knowledge, one of the highest percentages of BRAF 
Table 3: Concordance between primary and metastatic samples as observed by three different methods and with the 
combination of at least two different techniques
 BRAF mutation Concordance (%)
Primary/Metastasis
Concordant Discordant  
 +/+ -/- +/- -/+
IHC 8 5 1 1 87
PNA* 6 4 5 0 67
Sanger* 2 3 5 2 42
At least two methods 6 4 5 0 67
*when different metastatic samples were considered for each case, partial concordance was considered as discordance (n.a.: 
not applicable; +/+: both primary and metastatic samples BRAF positive; -/-: both primary and metastatic samples BRAF 
negative; +/-: primary sample BRAF positive and metastatic sample(s) BRAF negative; -/+: primary sample BRAF negative 
and metastatic sample(s) BRAF positive).
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mutations reported in the literature [4, 5, 7]. To our 
knowledge PNAs have been described one time only, very 
recently, for BRAF detection in melanomas; in addition 
they have been efficiently applied to BRAF testing for 
colorectal cancer and papillary thyroid carcinoma (PTC) 
[31, 37–40].
Two issues may justify this high percentage of 
mutated samples: the high sensitivity of PNA (compared 
to IHC and most to Sanger Sequencing) and the high 
prevalence, in our population, of melanomas in sites not 
chronically sun exposed (CSE) as trunk and limbs (Table 1), 
which are known to be associated with BRAF mutation [41].
The use of three different methods was useful 
in identifying the method with higher sensitivity and 
concordance compared to the others. Data obtained with 
IHC and PNA were quite consistent, while data obtained 
with capillary sequencing confirmed the difficulty in 
identifying a mutated allele when the percentage of tumor 
cells was below a threshold (which is generally considered 
to be 50%), in addition to the difficulty of working with 
little DNA, as in small primary melanoma, limiting PCR 
amplification prior to sequencing.
We conclude that PNA testing in primary melanoma 
is highly specific and reliable in detecting even a small 
fraction of mutated allele, undetectable with other methods 
(Figure 1F) making PNA, which is CE-IVD approved, 
applicable in clinical practice. Limitations in the choice of 
this technique could be its higher cost if compared to IHC 
[31] and dependence on DNA extraction.
While BRAF V600E mutation appears to play a 
critical role in tumor initiation, its expression during tumor 
progression remains controversial. Various authors claim 
that BRAF V600E heterogeneity present in melanoma, 
could be due to tumor sampling, the detection method 
used, or secondary to biological differences [18, 21, 
22, 24, 43, 44]. Since coexistence of BRAF wild-type 
Figure 2: NGS results of 4 samples from three different patients. A. BRAF NGS of Case 4 primary melanoma, which shows a 
mutant allele percentage of 30%. B. Case 4 melanoma metastasis, positive for NRAS Q61R mutation (mutant allele 74%); the same sample 
was BRAF wild type (not shown). C-D. BRAF results for other two primary melanomas (case 13 and 25), whose metastases were BRAF 
wild type; primary tissues presented 47% and 41% of BRAF mutant alleles respectively.
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and BRAF mutant tumor cells within the same patient 
has important implications for clinical decisions, more 
sophisticated tools are needed to characterize patients’ 
cancers and guide their treatment.
With the aim to evaluate the issue of possible 
intertumoral heterogeneity in our cohort, we used the same 
three-methods approach, mentioned above, on 25 matched 
primary and metastatic samples from 15 patients in our 
cohort. In several papers, relying mainly on IHC, BRAF 
expression is assumed to be homogeneous in the majority 
of the lesions from the same patients [17, 23]. In our 
cohort, a consistency of nearly 90% was found using IHC, 
which supports this observation (Table 3). The addition 
of molecular techniques further clarifies that the observed 
heterogeneity is not due to the single techniques used. 
We observed that 10 (67%) cases showed consistency 
between primary and metastases for BRAF mutational 
status (6 mutated and 4 wild type), when assessed with 
at least two methods. In 5 cases there was no consistency, 
all the cases had a BRAF mutation in the primary which 
was not identified in the subsequent metastases. This result 
partially supports recent large studies in which, in the 
majority of cases, the primary and metastatic lesions had 
the same BRAF genotype [20, 45]. Indeed, we observed 
a good but not complete consistency between primary 
and metastatic samples from the same patients (10/15) 
while different metastatic lesions from the same patients 
revealed a concordant BRAF status.
The finding that BRAF mutations in primary 
melanomas is not always identified in the correspondent 
metastases can also partly explain the high percentage 
of BRAF mutations observed in our cohort of primary 
tumors (62% with at least two methods) compared to the 
literature, in which only metastatic tissue is evaluated. 
In addition, the natural history of the disease and the 
occurrence of multiple primary melanoma in the same 
patients should always be considered.
Overall, despite our 15 patients analyzed represent 
the 68% of the cases which relapsed, our results are 
limited by the small numbers and the mutation testing of 
only for BRAF gene.
While it is still unclear what is the selective pressure 
that induces migration of a BRAF-wild-type subclone 
instead of an expected more aggressive BRAF-mutant 
subclone, an approach based on NGS targeting multigene 
panels could help in clarifying this issue. Finally a recent 
study using NGS identifies very low heterogeneity in 
matched primary and lymph node metastatic samples, 
especially in synchronous metastases, while heterogeneity 
is more frequent in metachronous lesions [46]. Our 
results, using the concordance between at least two 
methods, confirm this finding, since our discordant cases 
displayed metastatic lymph-nodes which were not excised 
synchronously with the primary tumor.
In conclusion, the intertumoral (primary and 
metastatic) heterogeneity described here is not attributable 
to technical issues when molecular methods are used, 
since it was observed with a combination of different 
technique and partially confirmed by a fourth, quantitative, 
technique as NGS.
A combination of IHC, used as a screening tool, 
and parallel formal molecular mutation testing seems to 
provide the highest reliability for identifying the majority 
of BRAF mutated cases with the highest sensitivity and 
specificity [47, 48]. The use of IHC alone, without parallel 
molecular testing should be limited to samples of small size 
or with low tumor cell content for optimal DNA extraction. 
Conversely, the use of very sensitive molecular techniques, 
which could detect a minor BRAF-mutated subclone in a 
predominantly wild-type tumor, may not be clinically 
relevant as BRAF inhibitors may have opposite signaling 
effects in cells with mutated or wild-type BRAF [23].
The limits of this approach are in the comparison of 
techniques with very different sensitivity (IHC vs PNA) 
and specificity with the capability to identify different 
cellular structure (proteins for IHC; DNA for molecular 
techniques). In addition, when a second molecular 
technique is necessary, the increase in turnaround time 
and costs is another possible limit to this type of approach.
In clinical practice we propose the analysis of the 
most recent and clinically relevant sample (metastatic 
when available) with IHC and at least one molecular 
method (in our case we propose PNA). If BRAF mutation 
is identified in PNA, but not with IHC a third analysis with 
another method (in our case capillary sequencing or, for a 
quantification, NGS or pyrosequencing) is recommended 
in order to obtain a concordance of at least two methods, 
or identification of another BRAF V600 mutation which 
is undetectable with VE1 antibody (Figure 3). Testing the 
primary tumor when the metastatic sample is unavailable 
is a good option if at least two methods of detection are 
used, however the presence of intertumoral heterogeneity 
or the occurrence of additional primaries should be 
carefully considered.
Interestingly, a recent study suggests that the 
staining pattern (homogeneous vs. heterogeneous) might 
be associated with differences in therapeutic response 
to BRAF inhibitors [19]. This is a field which will need 
further investigation in the near future and parallel 
IHC testing, which is currently being developed with 




A total of 137 melanoma samples were included. 
100 primary melanomas were selected based on formalin-
fixed, paraffin embedded (FFPE) tissue availability at the 
Pathology department, IRCCS AOU San Martino IST, 
Genoa.
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All melanoma patients had been referred to our 
center for germline testing either for diagnostic (familial 
and multiple melanoma cases) or research purposes 
(sporadic cases from an ongoing case-control study [26–
28]). All the patients signed an informed consent under 
local IRB approved protocols for both germline testing 
and other research purposes dealing with the archived 
melanoma tissues in the pathology department. A local 
database collecting information from the pathology report, 
tumor cell content, in the examined section, and follow-
up was designed. The database is regularly updated with 
the oncologists’ and local registries database, and includes 
detailed information on relapse, survival, time and cause 
of death.
A total of 25 metastatic samples, from 15 patients, 
were available and tested with the same techniques used 
for the primary tumors. Twelve metastatic samples, 
already tested for diagnostic purposes by molecular 
techniques, were used as positive and negative controls 
for IHC assessment (4 BRAF positive e 8 negative).
DNA extraction
All diagnoses were performed by two expert 
dermatopathologists (FC and MG), and subsequently 
reviewed for tumor content, neoplastic cell morphology 
(epithelioid vs spindled) and immunohistochemistry 
evaluation (LM and FG).
The tumor area was identified, and marked by the 
pathologists, on hematoxylin and eosin stained slides. 
Marked tumor tissue was manually dissected from two to 
six slides (8-micron thick) of FFPE tissue for each case.
Genomic DNA was extracted from the sections 
using the QIAmp DNA FFPE tissue kit (Qiagen, Valencia, 
CA, USA) or the Genomic DNA FFPE One-Step Kit for 
Diatech MagCore® HF16Plus extractor (RBC Bioscience, 
New Taipei City, Taiwan), in both cases according to the 
manufacturer’s instructions. Quality and concentration of 
the DNA samples were examined by SPECTROstar Nano 
(BMG Labtech, Offenburg, Germany).
Figure 3: Diagnostic algorithm proposed for BRAF testing in metastatic melanoma. Report is based on the results obtained 
with two concordant methods. Applicable also to primary tumors when needed.
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Capillary sequencing
Capillary sequencing was performed as previously 
described [29–31]. Briefly, we amplified tumor DNA in 
a 15 μl PCR containing approximately 40 ng of purified 
genomic DNA in a mixture of 1.5 μl of Buffer (10x), 1.5 μl 
dNTP (2 mM), 0.08 μl Qiagen HotStart Taq (5U/μl) and 2 
μl forward and reverse primer (5 mM). After denaturation 
at 95°C for 15 minutes, 35 amplification cycles at 95°C for 
40s, 60°C for 30s, 72°C for 50s followed by elongation at 
72°C for 10 minutes were performed.
Sequencing was conducted with Big Dye Terminator 
sequencing kit v1.1 (Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s instructions, and 
sequencing reactions were electrophoresed on an ABI 
3130xl genetic analyzer (Applied Biosystems, Carlsbad, 
CA, USA). Sequencing reactions were repeated at least 
twice by independent PCR, with forward and reverse 
primers, and the sample was scored as being mutated when 
the mutation was observed both times. BRAF primers for 
amplification of exon 15, used for both PCR and Capillary 
sequencing were previously described [31].
PNA clamping quantitative PCR analysis
BRAF V600 codon mutational status was tested 
using the PNAClamp™ BRAF Mutation Detection Kit 
(Panagene, Daejeon, Korea), a CE-IVD certified technique 
based on peptide nucleic acid (PNA)-mediated real-time 
PCR clamping technology. PNA is a synthetic DNA 
analog in which the phosphodiester backbone is replaced 
by a peptide-like repeat formed by (2-aminoethyl)-glycine 
units. The technique is based on the principle that PNA 
inhibits wild type by hybridizing normal sequences, and 
therefore mutant DNA is preferentially amplified.
The reaction was performed according to the 
manufacturer's instructions, with slight modifications, as 
previously described [31]. The threshold cycle (Ct) was 
automatically calculated from the PCR amplification plots 
where fluorescence was plotted against the number of 
cycles. Delta-Ct values were calculated as the Ct values 
of the samples minus those of the controls. The higher 
delta-Ct values showed that the mutant was efficiently 
amplified. A cut-off value of 2.0 was used to determine 
the presence of mutant DNA.
Immunohistochemistry
Immunohistochemistry was performed using the 
BRAF V600E mutation-specific antibody (Springer-
Bio, clone VE1, 1:50 dilution). Four micron-thick tissue 
sections were freshly cut [32], dried, deparaffinised and 
rehydrated. Endogenous peroxidase was blocked with 5% 
H2O2 for 10 minutes. Immunoreactions were performed 
using the automated BenchMark XT immunostainer® 
(Ventana Medical Systems, Arizona, USA). Standard heat-
based antigen retrieval was performed for 30 minutes. The 
ultraVIEW Universal Alkaline Phosphatase Red Detection 
Kit (Ventana Medical Systems, Arizona, USA), was used. 
After immunostaining, slides were counterstained with 
haematoxylin and coverslipped. All reactions were carried 
out on the same day on consecutive runs and positive 
and negative controls were added for each run. Positive 
and negative controls used were chosen from metastatic 
samples already characterized for BRAF molecular status 
for diagnostic purposes (both Capillary sequencing and PNA 
clamping real-time PCR, as performed by the manufacturer).
All immunostained slides were simultaneously 
scored by two pathologists (LM and FG) blinded to the 
BRAF status; disagreement was resolved by consensus. IHC 
was considered positive when BRAF V600E cytoplasmic 
protein expression was scored according to the 3 categories 
score used by Tetzlaff et al [33]. Briefly, negative staining 
was defined as either absence of any cytoplasmic labeling 
or nuclear staining only in melanoma cells; positive staining 
was distinguished in either positive homogeneous (staining 
in > 95% of cells) or positive heterogeneous (staining in < 
95% of cells) based on percentage of cytoplasmic staining 
in melanoma cells; intensity of staining was also scored as 
weak, moderate or strong.
Next generation sequencing
Re-analysis of primary and metastatic samples 
showing discordant results with the other techniques 
from 3 selected patients was performed by targeted next 
generation sequencing (NGS) as previously described 
[31]. Briefly, 10 nanograms of DNA were amplified 
with an in-house, customized Ion AmpliSeq primer tool, 
comprising 32 amplicons of 19 genes, targeting 79 hotspot 
mutations, including the hotspot exon 15 of the BRAF 
gene. PCR products were ligated to adapters and enriched 
for target regions using the Ion AmpliSeq™ Library Kit 
2.0 according to the manufacturer’s instructions (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). The 
samples were quality checked for proper amplicon 
length and quantity on the 2100 Bioanalyzer Instruments 
(Agilent Technologies, Santa Clara, California, USA), 
then sequenced on the Ion Personal Genome Machine™ 
(PGM™) System. Data were analyzed using the Torrent 
Suite Software, version 5.0.4.0 (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) and visualized in the 
integrative genome viewer (IGV); annotation was 
performed by Ion Reporter™ Software (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA).
Inter-rater agreement
To measure agreement between 3 techniques 
(Sanger sequencing, PNA and IHC) in determining 
BRAF mutational status, we computed the Light’s Kappa 
coefficient [34]. The analysis was performed using the IRR 
package [35] within the R computational environment (R 
Foundation for Statistical Computing, Vienna, Austria) [36].
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